Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...

全面介紹

Gespeichert in:
書目詳細資料
Autoren: Otte, Katharina, Zhao, Kai, Braun, Madita, Neubauer, Andreas, Raifer, Hartmann, Helmprobst, Frederik, Barrera, Felipe Ovalle, Nimsky, Christopher, Bartsch, Jörg W., Rusch, Tillmann
格式: Artikel
語言:英语
出版: Philipps-Universität Marburg 2022
主題:
在線閱讀:PDF-Volltext
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

因特網

PDF-Volltext

持有資料詳情
索引號: urn:nbn:de:hebis:04-es2023-00588
Publikationsdatum: 2023-05-16
Quelle: Erstveröffentlichung: Otte, K.; Zhao, K.; Braun, M.; Neubauer, A.; Raifer, H.; Helmprobst, F.; Barrera, F.O.; Nimsky, C.; Bartsch, J.W.; Rusch, T. Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines 2022, 10, 2145. https://doi.org/10.3390/biomedicines10092145
Downloads: 14 (2024), 44 (2023)
Lizenz: https://creativecommons.org/licenses/by/4.0
Zugangs-URL: https://archiv.ub.uni-marburg.de/es/2023/0058
https://doi.org/10.3390/biomedicines10092145